Tevogen Bio (NASDAQ:TVGN) Trading Down 0.3% - Time to Sell?

Key Points

• Tevogen Bio's stock decreased by 0.3%, trading at $0.79 with a notable drop in trading volume of 62% from average levels.
• Analysts maintain a buy rating for Tevogen Bio with a target price of $10.00, despite recent volatility in share performance.
• The company reported earnings per share of ($0.03), exceeding analysts' expectations of ($0.05) in its last quarterly earnings.

Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) fell 0.3% on Tuesday . The stock traded as low as $0.78 and last traded at $0.79. 208,679 shares were traded during trading, a decline of 62% from the average session volume of 549,448 shares. The stock had previously closed at $0.79.

Analyst Ratings Changes

Separately, D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Tevogen Bio in a research note on Thursday, September 4th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $10.00.

Tevogen Bio Stock Down 0.3%

The firm has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $1.07. The stock has a market cap of $154.48 million, a PE ratio of -4.13 and a beta of -0.78.

Tevogen Bio (NASDAQ:TVGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 19th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02.

Hedge Funds Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Nuveen LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 90,253 shares of the company's stock, valued at approximately $97,000.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.